Oxidized LDL and the metabolic syndrome

Bibliography

• Adult Treatment Panel III: Executivesummary of the third report of the NationalCholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation, andTreatment of High Blood Cholesterol inAdults. JAMA 285, 2486–2497 (2001)
   Google Scholar
• Ford ES: The metabolic syndrome andmortality from cardiovascular disease andall-causes: fi ndings from the National Healthand Nutrition Examination Survey IIMortality Study. Atherosclerosis 173(2),309–314 (2004)
   Google Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI,Smith SC Jr, Lenfant C: Defi nition ofmetabolic syndrome: report of theNational Heart, Lung, and BloodInstitute/American Heart Associationconference on scientifi c issues related todefi nition. Circulation 109(3), 433–438(2004)
   Google Scholar
• Kahn R, Buse J, Ferrannini E, Stern M:The metabolic syndrome: time for acritical appraisal: joint statement from theAmerican Diabetes Association and theEuropean Association for the Study ofDiabetes. Diabetes Care 28(9), 2289–2304(2005)
   Google Scholar
• Girman CJ, Rhodes T, Mercuri M et al.:The metabolic syndrome and risk of majorcoronary events in the ScandinavianSimvastatin Survival Study (4S) and the AirForce/Texas Coronary AtherosclerosisPrevention Study (AFCAPS/TexCAPS).Am. J. Cardiol. 93(2), 136–141 (2004)
   Google Scholar
• Hunt KJ, Resendez RG, Williams K,Haffner SM, Stern MP: NationalCholesterol Education Program versusWorld Health Organization metabolicsyndrome in relation to all-cause andcardiovascular mortality in the SanAntonio Heart Study. Circulation 110(10),1251–1257 (2004)
   Google Scholar
• Isomaa B, Henricsson M, Almgren P,Tuomi T, Taskinen M R, Groop L:The metabolic syndrome infl uences therisk of chronic complications in patientswith Type II diabetes. Diabetologia 44(9),1148–1154 (2001)
   Google Scholar
• Lakka HM, Laaksonen DE, Lakka TAet al.: The metabolic syndrome and totaland cardiovascular disease mortality inmiddle-aged men. JAMA 288(21),2709–2716 (2002)
   Google Scholar
• Lempiainen P, Mykkanen L, Pyorala K,Laakso M, Kuusisto J: Insulin resistancesyndrome predicts coronary heart diseaseevents in elderly nondiabetic men.Circulation 100(2), 123–128 (1999)
   Google Scholar
• Malik S, Wong ND, Franklin SS et al.:Impact of the metabolic syndrome onmortality from coronary heart disease,cardiovascular disease and all causes inUnited States adults. Circulation 110(10),1245–1250 (2004)
   Google Scholar
• Onat A, Ceyhan K, Basar O, Erer B,Toprak S, Sansoy V: Metabolic syndrome:major impact on coronary risk in apopulation with low cholesterol levels –a prospective and cross-sectional evaluation.Atherosclerosis 165(2), 285–292 (2002)
   Google Scholar
• Stern M P, Williams K, Hunt KJL:Impact of diabetes/metabolic syndromein patients with established cardiovasculardisease. Atheroscler. Suppl. 6(2), 3–6(2005)
   Google Scholar
• Goetz FC, Roel J, Jacobs DR Jr et al.:Declining β-cell function in Type 2diabetes: 5-year follow-up andimmunologic studies of the population ofWadena, MN. Metabolism 51(2), 144–148(2002)
   Google Scholar
• Fagerberg B, Bondjers L, Nilsson P:Low birth weight in combination withcatch-up growth predicts the occurrence ofthe metabolic syndrome in men at latemiddle age: the Atherosclerosis and InsulinResistance study. J. Intern. Med. 256(3),254–259 (2004)
   Google Scholar
• Sinaiko A R, Steinberger J, Moran A et al.:Relation of body mass index and insulinresistance to cardiovascular risk factors,infl ammatory factors and oxidative stressduring adolescence. Circulation 111(15),1985–1991 (2005)
   Google Scholar
• Sjoholm A, Nystrom T: Infl ammationand the etiology of Type 2 diabetes.Diabetes Metab. Res. Rev. 22(1), 4–10(2006)
   Google Scholar
• James P T, Leach R, Kalamara E,Shayeghi M: The worldwide obesityepidemic. Obes. Res. 9(Suppl. 4), 228S–233S(2001)
   Google Scholar
• James P T, Rigby N, Leach R: The obesityepidemic, metabolic syndrome and futureprevention strategies. Eur. J. Cardiovasc.Prev. Rehabil. 11(1), 3–8 (2004)
   Google Scholar
• York DA, Rossner S, Caterson I et al.:Prevention Conference VII: Obesity, aworldwide epidemic related to heart diseaseand stroke: Group I: worldwidedemographics of obesity. Circulation 110(18),E463–E470 (2004)
   Google Scholar
• Fonseca V, Desouza C, Asnani S, Jialal I:Nontraditional risk factors for cardiovasculardisease in diabetes. Endocr. Rev. 25(1),153–175 (2004)
   Google Scholar
• Duncan BB, Schmidt MI, Pankow JSet al.: Low-grade systemic infl ammationand the development of Type 2 diabetes:the atherosclerosis risk in communitiesstudy. Diabetes 52(7), 1799–1805 (2003)
   Google Scholar
• Pradhan AD, Manson JE, Rifai N,Buring JE, Ridker PM: C-reactiveprotein, interleukin 6, and risk ofdeveloping Type 2 diabetes mellitus.JAMA 286(3), 327–334 (2001)
   Google Scholar
• Heilbronn LK, Campbell LV: Adiposetissue macrophages, low grade infl ammationand insulin resistance in human obesity.Curr. Pharm. Des. 14(12), 1225–1230(2008)
   Google Scholar
• Reilly MP, Lehrke M, Wolfe ML, Rohatgi A,Lazar MA, Rader D J: Resistin is aninfl ammatory marker of atherosclerosis inhumans. Circulation 111(7), 932–939(2005)
   Google Scholar
• Cipolletta C, Ryan KE, Hanna EV,Trimble ER: Activation of peripheralblood CD14+ monocytes occurs indiabetes. Diabetes 54 (9), 2779–2786(2005)
   Google Scholar
• Furukawa S, Fujita T, Shimabukuro Met al.: Increased oxidative stress inobesity and its impact on metabolicsyndrome. J. Clin. Invest. 114(12),1752–1761 (2004)
   Google Scholar
• Mertens A, Verhamme P, Bielicki JKet al.: Increased low-density lipoproteinoxidation and impaired high-densitylipoprotein antioxidant defense areassociated with increased macrophagehoming and atherosclerosis in dyslipidemicobese mice: LCAT gene transfer decreasesatherosclerosis. Circulation 107(12),1640–1646 (2003)
   Google Scholar
• Mertens A, Holvoet P: Oxidized LDLand HDL: antagonists in atherothrombosis.FASEB J. 15(12), 2073–2084 (2001)
   Google Scholar
• Hansel B, Giral P, Nobecourt E et al.:Metabolic syndrome is associated withelevated oxidative stress and dysfunctionaldense high-density lipoprotein particlesdisplaying impaired antioxidative activity.J. Clin. Endocrinol. Metab. 89(10),4963–4971 (2004)
   Google Scholar
• Mastorikou M, Mackness M, Mackness B:Defective metabolism of oxidizedphospholipid by HDL from people withType 2 diabetes. Diabetes 55(11), 3099–3103(2006)
   Google Scholar
• McLaughlin T, Abbasi F, Kim HS,Lamendola C, Schaaf P, Reaven G:Relationship between insulin resistance,weight loss and coronary heart disease risk inhealthy, obese women. Metabolism 50(7),795–800 (2001)
   Google Scholar
• Verreth W, De Keyzer D, Pelat Met al.: Weight-loss-associated inductionof peroxisome proliferator-activatedreceptor-alpha and peroxisome prolife ratoractivatedreceptor-γ correlate withreduced atherosclerosis and improvedcardiovascular function in obeseinsulin-resistant mice. Circulation 110(20),3259–3269 (2004).
   Google Scholar
• Reveals the associations betweenweight loss-induced improvement ofinsulin sensitivity in adipose tissue,the induction of PPARs and the reductionof oxidative stress in the vascular cells.This fi nding is important in view of theearlier report [31] demonstrating thatweight loss reduces cardiovascular riskmore in insulin-resistant than ininsulin-sensitive obese women.
   Google Scholar
• Costa A, Casamitjana R, Casals E et al.:Effects of atorvastatin on glucosehomeostasis, post- prandial triglycerideresponse and C-reactive protein in subjectswith impaired fasting glucose. Diabet. Med.20(9), 743–745 (2003)
   Google Scholar
• Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C:Effects of a statin group drug, pravastatin, onthe insulin resistance in patients withmetabolic syndrome. Biomed. Pharmacother.58(10), 614–618 (2004)
   Google Scholar
• Paniagua JA, Lopez-Miranda J, Escribano Aet al.: Cerivastatin improves insulinsensitivity and insulin secretion in early-stateobese Type 2 diabetes. Diabetes 51(8),2596–2603 (2002).
   Google Scholar
• Demonstrates that a statin increasesinsulin sensitivity associated withdecreased lipid oxidation.
   Google Scholar
• Sonmez A, Baykal Y, Kilic M et al.:Fluvastatin improves insulin resistance innondiabetic dyslipidemic patients. Endocrine22(2), 151–154 (2003)
   Google Scholar
• Parker R A, Huang Q, Tesfamariam B:Infl uence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors onendothelial nitric oxide synthase and theformation of oxidants in the vasculature.Atherosclerosis 169(1),19–29 (2003)
   Google Scholar
• Stoll LL, McCormick ML, Denning GM,Weintraub NL: Antioxidant effects of statins.Drugs Today (Barc.) 40(12), 975–990(2004)
   Google Scholar
• Wagner AH, Kohler T, Ruckschloss U, Just I,Hecker M: Improvement of nitric oxidedependentvasodilatation by HMG-CoAreductase inhibitors through attenuation ofendothelial superoxide anion formation.Arterioscler. Thromb. Vasc. Biol. 20(1), 61–69(2000)
   Google Scholar
• Verreth W, De Keyzer D, Davey PC et al.:Rosuvastatin restores superoxide dismutaseexpression and inhibits accumulation ofoxidized LDL in the aortic arch of obesedyslipidemic mice. Br. J. Pharmacol. 151(3),347–355 (2007)
   Google Scholar
• Desjardins F, Sekkali B, Verreth Wet al.: Rosuvastatin increases vascularendothelial PPARγ expression and correctsblood pressure variability in obesedyslipidaemic mice. Eur. Heart J. 29(1),128–137 (2008)
   Google Scholar
• Ehara S, Ueda M, Naruko T et al.: Elevatedlevels of oxidized low density lipoproteinshow a positive relationship with the severityof acute coronary syndromes. Circulation103(15), 1955–1960 (2001)
   Google Scholar
• Tsimikas S, Bergmark C, Beyer RW et al.:Temporal increases in plasma markers ofoxidized low-density lipoprotein stronglyrefl ect the presence of acute coronarysyndromes. J. Am. Coll. Cardiol. 41(3),360–370 (2003)
   Google Scholar
• Holvoet P, Vanhaecke J, Janssens S,Van deWerf F, Collen D: Oxidized LDL andmalondialdehyde-modifi ed LDL in patientswith acute coronary syndromes and stablecoronary artery disease. Circulation 98(15),1487–1494 (1998)
   Google Scholar
• Holvoet P, Mertens A, Verhamme P et al.:Circulating oxidized LDL is a useful markerfor identifying patients with coronary arterydisease. Arterioscler. Thromb. Vasc. Biol.21(5), 844–848 (2001)
   Google Scholar
• Holvoet P, Macy E, Landeloos M et al.:Analytical performance and diagnosticaccuracy of immunometric assays for themeasurement of circulating oxidized LDL.Clin. Chem. 52(4), 760–764 (2006)
   Google Scholar
• Tsimikas S, Brilakis ES, Miller ER et al.:Oxidized phospholipids, Lp(a) lipoprotein,and coronary artery disease. N. Engl. J. Med.353(1), 46–57 (2005)
   Google Scholar
• Bergmark C, Dewan A, Orsoni A et al.:A novel function of lipoprotein [a] as apreferential carrier of oxidized phospholipidsin human plasma. J. Lipid. Res. 49(10),2230–2239 (2008)
   Google Scholar
• Van Berkel TJ, De Rijke Y B, Kruijt JK:Different fate in vivo of oxidatively modifi edlow density lipoprotein and acetylated lowdensity lipoprotein in rats. Recognition byvarious scavenger receptors on Kupffer andendothelial liver cells. J. Biol. Chem. 266(4),2282–2289 (1991)
   Google Scholar
• Avogaro P, Bon GB, Cazzolato G: Presenceof a modifi ed low density lipoprotein inhumans. Arteriosclerosis 8(1), 79–87 (1988)
   Google Scholar
• Shoji T, Nishizawa Y, Fukumoto M et al.:Inverse relationship between circulatingoxidized low density lipoprotein (oxLDL)and anti-oxLDL antibody levels in healthysubjects. Atherosclerosis 148(1), 171–177(2000)
   Google Scholar
• Lamarche B: Abdominal obesity and itsmetabolic complications: implications for therisk of ischaemic heart disease. Coron. ArteryDis. 9(8), 473–481 (1998)
   Google Scholar
• Holvoet P, Harris TB, Tracy RP et al.:Association of high coronary heart diseaserisk status with circulating oxidized LDL inthe well-functioning elderly: fi ndings fromthe Health, Aging and Body Compositionstudy. Arterioscler. Thromb. Vasc. Biol. 23(8),1444–1448 (2003)
   Google Scholar
• Butler J, Rodondi N, Zhu Y et al.: Metabolicsyndrome and the risk of cardiovasculardisease in older adults. J. Am. Coll. Cardiol.47(8), 1595–1602 (2006)
   Google Scholar
• Holvoet P, Kritchevsky SB, Tracy RP et al.:The metabolic syndrome, circulatingoxidized LDL and risk of myocardialinfarction in well-functioning elderlypeople in the health, aging, and bodycomposition cohort. Diabetes 53(4),1068–1073 (2004).
   Google Scholar
• First report supporting the relationshipbetween metabolic syndrome and elevatedplasma oxidized LDL and the high risk ofacute cardiovascular events.
   Google Scholar
• Holvoet P, Jenny NS, Schreiner PJ, Tracy RP,Jacobs DR: The relationship betweenoxidized LDL and other cardiovascular riskfactors and subclinical CVD in differentethnic groups: the Multi-Ethnic Study ofAtherosclerosis (MESA). Atherosclerosis194(1), 245–252 (2007)
   Google Scholar
• Lapointe A, Couillard C, Piche ME et al.:Circulating oxidized LDL is associated withparameters of the metabolic syndrome inpostmenopausal women. Atherosclerosis191(2), 362–368 (2007)
   Google Scholar
• Weinbrenner T, Schroder H, Escurriol Vet al.: Circulating oxidized LDL is associatedwith increased waist circumferenceindependent of body mass index in men andwomen. Am. J. Clin. Nutr. 83(1), 30–35(2006)
   Google Scholar
• Yamagishi SI, Matsuoka H, Kitano S et al.:Elevated circulating oxidized LDL levels inJapanese subjects with the metabolicsyndrome. Int. J. Cardiol.118(2), 270–272(2007)
   Google Scholar
• Johnston N, Jernberg T, Lagerqvist B,Siegbahn A, Wallentin L: Improvedidentifi cation of patients with coronary arterydisease by the use of new lipid andlipoprotein biomarkers. Am. J. Cardiol.97(5), 640–645 (2006)
   Google Scholar
• Meisinger C, Baumert J, Khuseyinova N,Loewel H, Koenig W: Plasma oxidizedlow-density lipoprotein, a strong predictor foracute coronary heart disease events inapparently healthy, middle-aged men fromthe general population. Circulation 112(5),651–657 (2005).
   Google Scholar
• Demonstrates that plasma oxidized LDL isthe strongest predictor of acutecardiovascular events compared with aconventional lipoprotein profi le and othertraditional cardiovascular risk factors.
   Google Scholar
• Cutter GR, Burke GL, Dyer AR et al.:Cardiovascular risk factors in youngadults. The CARDIA baseline monograph.Control. Clin. Trials 12(Suppl. 1), 1S–77S(1991)
   Google Scholar
• Friedman GD, Cutter GR, Donahue RPet al.: CARDIA: study design, recruitmentand some characteristics of the examinedsubjects. J. Clin. Epidemiol. 41(11),1105–1116 (1988)
   Google Scholar
• Holvoet P, Lee DH, Steffes M, Gross M,Jacobs DR Jr: Association betweencirculating oxidized low-density lipoproteinand incidence of the metabolic syndrome.JAMA 299(19), 2287–2293 (2008).
   Google Scholar
• Identifi es plasma oxidized LDL,independent of LDL cholesterol, as a riskfactor for metabolic syndrome and itscomponents obesity, hyperglycemiaand hypertriglyceridemia.
   Google Scholar
• Masella R, Vari R, D'Archivio M et al.:Oxidised LDL modulate adipogenesis in3T3-L1 preadipocytes by affecting thebalance between cell proliferation anddifferentiation. FEBS Lett. 580(10),2421–2429 (2006)
   Google Scholar
• Nishimura S, Manabe I, Nagasaki M et al.:Adipogenesis in obesity requires closeinterplay between differentiating adipocytes,stromal cells, and blood vessels. Diabetes56(6), 1517–1526 (2007)
   Google Scholar
• Stengel D, Antonucci M, Gaoua W et al.:Inhibition of LPL expression in humanmonocyte-derived macrophages is dependenton LDL oxidation state: a key role forlysophosphatidylcholine. Arterioscler.Thromb. Vasc. Biol. 18(7), 1172–1180(1998)
   Google Scholar
• Merkel M, Heeren J, Dudeck W et al.:Inactive lipoprotein lipase (LPL) aloneincreases selective cholesterol esteruptake in vivo, whereas in the presence ofactive LPL it also increases triglyceridehydrolysis and whole particle lipoproteinuptake. J. Biol. Chem. 277(9), 7405–7411(2002)
   Google Scholar
• Ouedraogo R, Wu X, Xu S Q et al.:Adiponectin suppression of high-glucoseinducedreactive oxygen species in vascularendothelial cells: evidence for involvementof a cAMP signaling pathway. Diabetes55(6), 1840–1846 (2006).
   Google Scholar
• Demonstrates that adiponectin reducesoxidative stress associated with highglucosein vascular cells.
   Google Scholar
• Goodpaster BH, Krishnaswami S, Harris TBet al.: Obesity, regional body fat distribution,and the metabolic syndrome in older menand women. Arch. Intern. Med. 165(7),777–783 (2005).
   Google Scholar
• Demonstrates that visceral obesity,associated with elevated oxidized LDL,is related to high risk of themetabolic syndrome.
   Google Scholar
• Maziere C, Morliere P, Santus R et al.:Inhibition of insulin signaling by oxidizedlow density lipoprotein. Protective effectof the antioxidant vitamin E. Atherosclerosis175(1), 23–30 (2004)
   Google Scholar
• Maddux BA, See W, Lawrence JC Jr,Goldfi ne AL, Goldfi ne ID, Evans JL:Protection against oxidative stress-inducedinsulin resistance in rat L6 muscle cells bymircomolar concentrations of α-lipoic acid.Diabetes 50(2), 404–410 (2001)
   Google Scholar
• Cnop M, Hannaert JC, Grupping AY,Pipeleers DG: Low density lipoproteincan cause death of islet β-cells by itscellular uptake and oxidative modifi cation.Endocrinology 143(9), 3449–3453 (2002)
   Google Scholar
• Bourdon E, Loreau N, Blache D:Glucose and free radicals impair theantioxidant properties of serum albumin.FASEB J. 13(2), 233–244 (1999)
   Google Scholar
• Koonen DP, Jacobs RL, Febbraio M et al.:Increased hepatic CD36 expressioncontributes to dyslipidemia associated withdiet-induced obesity. Diabetes 56(12),2863–2871 (2007)
   Google Scholar
• Krauss RM, Burke DJ: Identifi cation ofmultiple subclasses of plasma low densitylipoproteins in normal humans. J. Lipid. Res.23(1) 97–104 (1982)
   Google Scholar
• Chancharme L, Therond P, Nigon F,Lepage S, Couturier M, Chapman MJ:Cholesteryl ester hydroperoxide lability is akey feature of the oxidative susceptibility ofsmall, dense LDL. Arterioscler. Thromb. Vasc.Biol. 19(3), 810–820 (1999)
   Google Scholar
• Lamarche B, Tchernof A, Moorjani Set al.: Small, dense low-density lipoproteinparticles as a predictor of the risk ofischemic heart disease in men. Prospectiveresults from the Quebec CardiovascularStudy. Circulation 95(1), 69–75 (1997)
   Google Scholar
• Ridker PM, Buring JE, Cook NR,Rifai N: C-reactive protein, themetabolic syndrome, and risk ofincident cardiovascular events: an 8-yearfollow-up of 14 719 initially healthyAmerican women. Circulation 107(3),391–397 (2003)
   Google Scholar
• Tracy RP, Lemaitre RN, Psaty BM et al.:Relationship of C-reactive protein to risk ofcardiovascular disease in the elderly. Resultsfrom the Cardiovascular Health Study andthe Rural Health Promotion Project.Arterioscler. Thromb. Vasc. Biol. 17(6),1121–1127 (1997)
   Google Scholar
• Knopp RH, Paramsothy P: Oxidized LDLand abdominal obesity: a key tounderstanding the metabolic syndrome.Am. J. Clin. Nutr. 83(1), 1–2 (2006)
   Google Scholar
• Linna MS, Borg P, Kukkonen-Harjula Ket al.: Successful weight maintenancepreserves lower levels of oxidized LDLachieved by weight reduction in obesemen. Int. J. Obes. (Lond.) 31(2),245–253(2007)
   Google Scholar
• Porreca E, Di F C, Moretta V et al.:Circulating leptin is associated withoxidized LDL in postmenopausal women.Atherosclerosis 175(1), 139–143 (2004)
   Google Scholar
• Rector RS, Warner SO, Liu Y et al.:Exercise and diet induced weight lossimproves measures of oxidative stress andinsulin sensitivity in adults withcharacteristics of the metabolic syndrome.Am. J. Physiol. Endocrinol. Metab. 293(2),500–506 (2007)
   Google Scholar
• Shin MJ, Hyun YJ, Kim OY, Kim JY,Jang Y, Lee JH: Weight loss effect oninfl ammation and LDL oxidation inmetabolically healthy but obese (MHO)individuals: low infl ammation and LDLoxidation in MHO women. Int. J. Obes.Lond. 30(10), 1529–1534 (2006)
   Google Scholar
• Vasankari T, Fogelholm M,Kukkonen-Harjula K et al.: Reducedoxidized low-density lipoprotein afterweight reduction in obese premenopausalwomen. Int. J. Obes. Relat. Metab. Disord.25(2), 205–211 (2001)
   Google Scholar
• Elkan AC, Sjoberg B, Kolsrud B,Ringertz B, Hafstrom I, Frostegard J:Gluten-free vegan diet induces decreasedLDL and oxidized LDL levels and raisedatheroprotective natural antibodies againstphosphorylcholine in patients withrheumatoid arthritis: a randomized study.Arthritis Res. Ther. 10(2), 34 (2008)
   Google Scholar
• Castilla P, Davalos A, Teruel JL et al.:Comparative effects of dietarysupplementation with red grape juice andvitamin E on production of superoxide bycirculating neutrophil NADPH oxidase inhemodialysis patients. Am. J. Clin. Nutr.87(4), 1053–1061 (2008)
   Google Scholar
• Neri S, Signorelli SS, Torrisi B et al.: Effectsof antioxidant supplementation onpostprandial oxidative stress and endothelialdysfunction: a single-blind, 15-day clinicaltrial in patients with untreated Type 2diabetes, subjects with impaired glucosetolerance, and healthy controls. Clin. Ther.27(11), 1764–1773 (2005)
   Google Scholar
• Choi S H, Chae A, Miller E et al.:Relationship between biomarkers of oxidizedlow-density lipoprotein, statin therapy,quantitative coronary angiography, andatheroma: volume observations from theREVERSAL (Reversal of Atherosclerosiswith Aggressive Lipid Lowering) study.J. Am. Coll. Cardiol. 52(1), 24–32 (2008)
   Google Scholar
• Ky B, Burke A, Tsimikas S et al.: Theinfl uence of pravastatin and atorvastatinon markers of oxidative stress inhypercholesterolemic humans. J. Am.Coll. Cardiol. 51 (17), 1653–1662 (2008)
   Google Scholar
• Paniagua JA, Lopez-Miranda J, Perez-Martinez P et al.: Oxidized-LDL levels arechanged during short-term serum glucosevariations and lowered with statin treatmentin early Type 2 diabetes: a study ofendothelial function and microalbuminuria.Diabet. Med. 22 (12), 1647–1656 (2005)
   Google Scholar
• Shin MJ, Chung N, Lee JH et al.: Effectsof simvastatin on plasma antioxidant statusand vitamins in hypercholesterolemicpatients. Int. J. Cardiol. 118(2), 173–177(2007)
   Google Scholar
• Tavridou A, Efthimiadis A, Efthimiadis I,Paschalidou H: Antioxidant effects ofsimvastatin in primary and secondaryprevention of coronary heart disease.Eur. J. Clin. Pharmacol. 62(6), 485–489(2006)
   Google Scholar
• Willcox BJ, Curb JD, Rodriguez BL:Antioxidants in cardiovascular health anddisease: key lessons from epidemiologicstudies. Am. J. Cardiol. 101(10A), 75D–86D(2008)
   Google Scholar
• Steinhubl SR: Why have antioxidants failedin clinical trials? Am. J. Cardiol. 101 (10A),14D–19D (2008).
   Google Scholar
• Although numerous in vitro and animalstudies have supported the role of oxidizedLDL in atherosclerosis, and epidemiologiccohort studies with large numbers of men,women and diverse populations have beenlargely supportive of this hypothesis,interventional trials have beencontroversial. Together with [95] thispaper discusses reasons for this mismatch.
   Google Scholar
• Levonen A L, Vahakangas E, Koponen J K,Yla-Herttuala S: Antioxidant gene therapyfor cardiovascular disease: current status andfuture perspectives. Circulation 117(16),2142–2150 (2008)
   Google Scholar
• Pashkow FJ, Watumull DG, Campbell CL:Astaxanthin: a novel potential treatment foroxidative stress and infl ammation incardiovascular disease. Am. J. Cardiol.101(10A), 58D–68D (2008).
   Google Scholar